KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Land & Improvements: 2013-2017

  • Regeneron Pharmaceuticals' Land & Improvements rose 85.51% to $192.8 million in Q4 2017 from the same period last year, while for Dec 2017 it was $192.8 million, marking a year-over-year increase of 85.51%. This contributed to the annual value of $192.8 million for FY2017, which is 85.51% up from last year.
  • As of Q4 2017, Regeneron Pharmaceuticals' Land & Improvements stood at $192.8 million, which was up 85.51% from $103.9 million recorded in Q4 2016.
  • In the past 5 years, Regeneron Pharmaceuticals' Land & Improvements ranged from a high of $192.8 million in Q4 2017 and a low of $2.8 million during Q4 2013.
  • Moreover, its 3-year median value for Land & Improvements was $103.9 million (2016), whereas its average is $124.8 million.
  • Data for Regeneron Pharmaceuticals' Land & Improvements shows a peak YoY skyrocketed of 2,711.63% (in 2015) over the last 5 years.
  • Over the past 5 years, Regeneron Pharmaceuticals' Land & Improvements (Quarterly) stood at $2.8 million in 2013, then remained steady at $2.8 million in 2014, then surged by 2,711.63% to $77.8 million in 2015, then surged by 33.51% to $103.9 million in 2016, then spiked by 85.51% to $192.8 million in 2017.
  • Its last three reported values are $192.8 million in Q4 2017, $103.9 million for Q4 2016, and $77.8 million during Q4 2015.